| Family: | Virtus ETF Solutions |
| Name: | Virtus LifeSci Biotech Products ETF |
| Inception Date: | 17-Dec-2014 |
| Termination Date: | |
| Investment Objective: | Virtus LifeSci Biotech Products ETF (the "Products Fund") is an exchange-traded fund incorporated in the USA. The Fund seeks investment results that correspond to the performance of the LifeSci Biotechnology Products Index. Products stage companies are typically more established companies with much clinical trial failure risk behind them. |
| Prospectus | |
| Top 10 Holdings | ||
| ImmunityBio Inc | IBRX | 6.7288% |
| Iovance Biotherapeutics Inc | IOVA | 2.7032% |
| Moderna Inc | MRNA | 2.6858% |
| Novavax Inc | NVAX | 2.2937% |
| Mirum Pharmaceuticals Inc | MIRM | 2.1448% |
| Roivant Sciences Ltd | ROIV | 2.0011% |
| Gilead Sciences Inc | GILD | 1.9495% |
| Day One Biopharmaceuticals Inc | DAWN | 1.9052% |
| Amgen Inc | AMGN | 1.8829% |
| BioCryst Pharmaceuticals Inc | BCRX | 1.8229% |
| Top 10 Holdings Weight: | 26.1% |
| Number of Holdings: | 64 |
| Shares Outstanding: | 600,004 |
| Total Net Assets: | 50,202,340 |
| NAV: | 83.62 |
| Net Expense Ratio: | 0.79% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | US |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | Biotech |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Domestic |
